Stock IMPAX LABORATORIES INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Impax Laboratories Inc Nasdaq

Equities

US45256B1017

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
BU
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
BU
Amneal Releases 2023 Environmental, Social and Governance Report
BU
Amneal Pharmaceuticals : Jefferies Global Healthcare Conference 2024
PU
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
BU
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
BU
Amneal to Participate at Upcoming Investor Conference
BU
Amneal Reports First Quarter 2024 Financial Results
AQ
Amneal Pharmaceuticals : First Quarter 2024 Earnings Presentation
PU
Amneal: Q1 Earnings Snapshot
AQ
Amneal Reports First Quarter 2024 Financial Results
BU
California is joining with a New Jersey company to buy a generic opioid overdose reversal drug
AQ
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
BU
Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine
AQ
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
BU
Amneal to Report First Quarter 2024 Results on May 3, 2024
BU
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
BU
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful
AQ
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.
PU
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMRX Stock
  4. Stock
  5. News Impax Laboratories Inc
  6. Press Releases